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ABSTRACT
Objective To explore the relationship between 
symptoms of chronic fatigue syndrome (CFS)/myalgic 
encephalomyelitis (ME) and fibromyalgia (FM). The 
hypothesis predicated that there would be no significant 
differences between the group’s symptom experience.
Design A quasiexperimental design. Structural equation 
modelling (SEM) and invariance testing.
Participants Males (M) and females (F) >16 with a confirmed 
diagnosis of CFS/ME or FM by a general practitioner or 
specialist. CFS/ME (n=101, F: n=86, M: n=15, mean (M) age 
M=45.5 years). FM (n=107, F: n=95, M: n=12, M=47.2 years).
Outcome measures Diagnostic criteria: the American 
Centers for Disease Control and Prevention (CDC) for 
CFS/ME and the American College of Rheumatology 
(ACR) criteria for FM. Additional symptom questionnaires 
measuring: pain, sleep quality, fatigue, quality of life, 
anxiety and depression, locus of control and self- esteem.
Results Invariance was confirmed with the exception 
of the American CDC Symptom Inventory, Fibromyalgia 
Impact Questionnaire and Hospital Anxiety and Depression 
Scale (p<0.05) based on five questions. Consequently, 
it was erroneous to conclude differences. Therefore, the 
Syndrome Model was created. SEM could not have tested 
the ACR previously, as it comprised a single data point. 
Thus, it was combined with these three questionnaires, 
increasing the data points, to create this new measurable 
model. Results confirmed no significant differences 
between groups (p=0.07 (p<0.05)).
Conclusion Participants responded in a similar manner 
to the questionnaire, confirming the same symptom 
experience. It is important to consider this in context with 
differing criteria and management guidelines, as this 
may influence diagnosis and the trajectory of patient’s 
management. With the biomedical cause currently unclear, 
it is the symptom experience and the impact on quality 
of life that is important. These findings are meaningful for 
patients, clinicians and policy development and support 
the requirement for future research.
BACKGROUND
Chronic fatigue syndrome (CFS)/myalgic 
encephalomyelitis (ME) and fibromyalgia 
(FM) are both identified as debilitating 
syndromes, with unclear/unknown aetiolo-
gies and no specific diagnostic tests or cure at 
the present time.1
CFS/ME and FM patients experience 
extensive polysymptomatology that affects 
all aspects of daily life, such as educational, 
economic and social, which has a great 
impact on their quality of life.2–7 Symptoms of 
CFS/ME include fatigue, headaches, muscle 
aches and pains, and/or joint pain.8 FM is 
characterised by chronic widespread muscu-
loskeletal pain, persisting for ≥3 months, 
with an exhaustive list of additional symp-
toms.4 5 Ambiguity regarding the accuracy of 
diagnostic classification of CFS/ME or FM 
may have significant ramifications in terms 
of the management offered and the trajec-
tory of patient care.6 9–11 Understanding the 
relationship between CFS/ME and FM is 
Strengths and limitations of this study
 ► To our knowledge, this is the first study to assess the 
symptom experience of chronic fatigue syndrome 
(CFS)/myalgic encephalomyelitis (ME) and fibromy-
algia (FM) using structural equation modelling.
 ► This study brings attention to an area of CFS/ME and 
FM that has not been researched for a number of 
years.
 ► Addresses the possible constraints to symptom 
management imposed by guidelines or a lack there-
of for CFS/ME and FM and highlights the importance 
of symptom management to improve health- related 
quality of life, which is forefront in the lived experi-
ence of CFS/ME and FM.
 ► The constraints of the sample size prevented the test-
ing of a model incorporating all the questionnaires.
 ► The use of generic questionnaires should be con-
sidered when assessing the symptoms of CFS/ME 
and FM, as their criteria- based questionnaires are 
biased towards the specific syndrome they were 
designed for.
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consequently vital in the delivery of effective, evidence- 
based and contextually appropriate clinical interven-
tions.6 12–14
Thirty- eight criteria exist for diagnosing CFS/ME, with 
the American Centers for Disease Control and Preven-
tion (CDC) Criteria being most frequently applied in 
research.15–17 This includes the National Institute for 
Health and Care Excellence (NICE) (2007) guidelines for 
CFS/ME, which are currently under review. The Amer-
ican College of Rheumatology (ACR)4 published the only 
diagnostic criteria for FM. This criterion was modified to 
focus on areas of pain and remove the controversial pain 
point assessment, which historically required patients to 
experience pain in 11 out of 18 highlighted points on the 
body when pressure was applied.5 Fibromyalgia Action 
submitted a proposal to NICE in 2007 recommending 
the development of guidelines, but this was subsequently 
rejected. The reasons cited were management/treatment 
of FM may be hindered by guidelines, as no diagnostic test 
exists and clinicians are not in agreement on the optimal 
management for FM.18 NICE stated that formal guide-
lines may create illness behaviour and hinder possible 
treatment options. This suggests that current guidelines 
may influence the restriction in management options 
offered to a patient with CFS/ME.
Research investigating whether CFS/ME and FM have 
the same underlying pathology is limited, and this may 
be an artefact of the traditional approach of diagnosing 
and managing these syndromes as two distinct entities.1 19 
The research available concludes that CFS/ME and FM 
share many symptoms, but they do not agree if these 
syndromes are equivalent.12 20–24 Most of these studies 
were performed prior to the development and publishing 
of the accepted American CDC Criteria15 for CFS/ME, 
and when the ACR4 diagnostic criterion for FM was in 
its infancy, and although important in the context of this 
study, may now be considered obsolescent. Much of the 
literature available may discuss both together; however, 
little research actually investigates if the symptom expe-
rience is the same.1 24 Although diagnosis and manage-
ment of CFS/ME and FM is improving, it is clear from 
the literature that there remains at this time no definitive 
biomedical cause identified, nor has there been a diag-
nostic test developed or a formal management strategy 
implemented. Diagnosis is a long drawn out process 
hindered by the subtle differences in the presenting 
symptoms such as location of pain and fatigue, where 
management options may be suitable for both CFS/ME 
and FM.8 11 14
Considering there has been little improvement in the 
clinical management for these patients, it was important 
to perform a study into the symptoms of CFS/ME and 
FM to create a contemporary understanding of the rela-
tionship. This is pertinent due to the restrictions that the 
NICE guidelines impose and the argument that has been 
presented as to why there are no FM guidelines. By re- ex-
amining the symptoms to improve the understanding of 
the relationship between them, and the challenges faced 
by patients, may provide evidence that CFS/ME and FM 
could be a single syndrome.
The purpose of this research was to assess the current 
relationship between the symptoms of CFS/ME and FM 
and to establish whether a relationship exists. In the 
absence of clear pathophysiology or diagnostic test, if the 
symptom experience is the same for both CFS/ME and 
FM, then this may have ramifications for the individual’s 
management. This process may identify new areas for 
review and be informative for medical practitioners who 
come into contact with CFS/ME and FM patients and 
influence care.
Aims and objectives
To perform structural equation modelling (SEM) and 
inform this study, preliminary work was undertaken 
by McKay et al25 to address and report the foundation 
objectives, which would form the basis of the research 
now reported. These aims were to identify and confirm 
the key occurring themes/symptoms of CFS/ME and 
FM, and the magnitude that these were experienced by 
the participants. Participants confirmed that they had 
received a formal diagnosis of CFS/ME and FM from a 
general practitioner (GP) or specialist and that they satis-
fied the requirements set out by their respective criteria. 
The demographic characteristics of the participants, such 
as age and gender, were established. In addition, the reli-
ability and validity of the questionnaires used to measure 
symptoms in the current sample were confirmed and 
reported. A web- based questionnaire was designed to use 
for data collection.
The aim of the current research was to undertake an 
exploratory study into the symptoms of CFS/ME and FM. 
The hypothesis predicated that there would be no signif-
icant differences between the group’s symptom experi-
ence. To address this hypothesis a number of objectives 
and strategies were undertaken to identify and assess the 
symptoms. These were to confirm if a relationship exists 





The sample included males and females from the general 
population who are >16 years of age and had a confirmed 
diagnosis of CFS/ME or FM by a GP or specialist. People 
self- selected to participate and were recruited through 
advertisements on the internet and through CFS/ME and 
FM self- help groups. In addition, people with CFS/ME 
were required to satisfy the American CDC Criteria for 
CFS/ME,15 and people with FM were required to satisfy 
the ACR criteria for FM.4
Exclusion
Exclusions were as a result of self- diagnosis, additional 
chronic conditions, anxiety and/or depression or 
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Table 1 Description of questionnaires used for data collection
Symptom Questionnaire Purpose Reliability Validity Author
  Specific questionnaire/ 
criteria
        
Diagnostic Criteria for 
CFS/ME
American Centers for 
Disease Control and 
Prevention Diagnostic 
Criteria (CDC) for CFS/
ME. Symptom inventory.
Diagnostic criteria. In addition, measures, frequency, 
intensity and duration of eight symptoms.
Good.
Cronbach’s alpha (α) 
ranging from 0.82 to 0.91













Diagnostic criteria for FM. n/a n/a Wolfe et al4
Symptom experience 
of FM
The Fibromyalgia Impact 
Questionnaire
Comprises 20 items to assess the impact of 
symptoms of FM on patients’ daily lives and their 
response to any management/treatment offered. 
Questions address patient’s function, pain level, 






with the Arthritis 
Impact Scale
(p<0.0001).55
  Burkhardt et 
al54
  Generic questionnaire         
Pain McGill Pain 
Questionnaire
Measures frequency and intensity of pain, namely: 
affective, evaluative, sensory and miscellaneous. 
There is a body diagram to indicate areas of pain, 
72 descriptor words to assess pain and pain rating 












Measures 20 items on five dimensions: general, 
physical, mental, reduced motivation and reduced 
activity. Each dimension contains four items: two 
items relating to fatigue and two items that are 
contraindicative of fatigue.
Good.
α>0.80 with average of 
0.84.
Stability r ≥ 0.72.28 57
Good.
p<0.001
High scores 0.77 
general fatigue, 0.7 
physical fatigue, 0.61 
reduced activity, 0.56 
reduced motivation 
mental fatigue 0.23 
(p<0.01).28 57
Smets et al28
Sleep quality The Pittsburgh Sleep 
Quality Index
Measures sleep over the period of 1 month. 
Comprising 19 items, generating seven component 
scores measuring: subjective sleep quality, sleep 
latency, sleep duration, habitual sleep efficiency, 
sleep disturbance, the use of sleeping medication 
and day- time dysfunction.
Good.
α>0.83.
Mean component scores 
r=0.58.
Individual items α>0.83.




Quality of life The SF-36 V2 
Questionnaire (SF-36 
V2)
Comprises 36 questions within eight domains of 
health namely: pain general health, vitality, physical 
functioning, social functioning, role limitations 
through physical problems, role limitations due to 
emotional problems and mental health including 
anxiety, depression, loss of behavioural/emotional 
control and physiological well- being.
Results in two summary components of health 
physical and mental well- being of the patient. Aims 
to identify the positive and negative aspects of health 
that are most important to patients.
Good.
α>0.7 in all aspects 







Anxiety and depression Hospital Anxiety and 
Depression Scale 
(HADS)
Measures anxiety and depression in non- psychiatric 
populations. Comprises 14 questions. Seven 
questions for anxiety (HADS- A) and seven questions 





Range 0.6-0.8.30 63 64
Zigmond and 
Snaith30
Ability to approach 
illness
Multidimensional Health 
Locus of Control Form C
Measures self- related beliefs, comprised four scales 
namely: internal, chance, doctors and other people. 
Internal and chance scales comprise six questions, 
and doctors and other people comprise three 












Self- esteem The Rosenberg Self- 
Esteem Scale
Measures 10 items related to self- esteem. Includes 
feelings of self- worth and self- acceptance with five 
positive worded questions and five negatively worded 
questions. The negative items have their scores 










            
Adapted from McKay et al.25
CFS/ME, chronic fatigue syndrome/myalgic encephalomyelitis; FM, fibromyalgia; SF, Short Form.
 on F









pen: first published as 10.1136/bm





4 Mckay PG, et al. BMJ Open 2021;11:e041947. doi:10.1136/bmjopen-2020-041947
Open access 
incomplete data sets. Suitability for inclusion was based 
on screening answers posed by the questionnaire.
Consent
Informed consent was confirmed electronically based 
on full written disclosure of the study. Consent could be 
retracted up to the point of data analysis.
Measures
Table 1 details the nine self- assessment questionnaires 
that were subjected to validity and reliability checks and 
used to reflect and measure the symptoms that impact 
people with CFS/ME and FM and include: the McGill 
Pain Questionnaire (MPQ)26; the Pittsburgh Sleep Quality 
Index27; the Multidimensional Fatigue Inventory (MFI)28; 
the Health- Related Quality of Life (HRQoL) (SF-36 V2) 
Questionnaire29; the Hospital Anxiety and Depression 
Scale (HADS)30; the Multidimensional Health Locus of 
Control Scale (MHLOC Form C)31 and the Rosenberg 
Self- Esteem Scale (RSES).32 These questionnaires were 
selected as they were identified as being able to measure 
the most frequently reported symptoms of CFS/ME and 
FM.
The American CDC Symptom Inventory, the diagnostic 
criterion for CFS/ME15 33 and the ACR diagnostic crite-
rion for FM,4 were selected as they are disease specific. 
The Fibromyalgia Impact Questionnaire (FIQ)34 was used 
as it was designed specifically to measure the symptom 
experience of FM.34 35 In addition, a questionnaire 
collecting sociodemographic information (eg, date of 
birth, sex, employment and educational level) and details 
relating to CFS/ME and FM (duration of illness, clinician 
who provided diagnosis and medical history) was used.
Sample size
Addressing the sample required to perform SEM is chal-
lenging as no closed form expression exists; however, 
sample sizes between 100 and 300 are sufficient to 
generate meaningful data.35 36 Prior to analysis, data were 
manually screened to confirm all sections of the question-
naire, and consent were fully completed and submitted. 
The final sample comprised 101 CFS/ME and 107 FM 
participants.
Data analysis
Descriptive statistics were used to report the demographic 
details. Individual scoring methods for each of the ques-
tionnaires confirmed participants experienced a number 
of debilitating symptoms and confirmed that the partic-
ipants fulfilled the requirements of the American CDC 
Criteria for CFS/ME15 and the ACR criteria for FM4 as 
reported by McKay et al.25
The preparatory work by McKay et al25 ascertained if it 
would be suitable to perform SEM on the symptoms of 
the CFS/ME and FM groups by identifying patterns that 
could be measured. The Mann- Whitney U test was used 
to test how likely any significant differences in the groups 
means are not due to chance.
In this study, SEM using Analysis of Moment Struc-
tures,35–43 addressed the hypothesis that no significant 
differences exist between the symptom experience of the 
CFS/ME and FM groups. This technique uses a combina-
tion of statistical processes including, factor, regression 
and path analysis, to test causal relationships between 
measured variables and latent constructs. In addition, 
invariance testing was performed to confirm if partici-
pants were approaching the questionnaires in a similar 
manner, confirming that they have the same symptom 
experience.
There are no standardised goodness of fit indices (GFI) 
to confirm the degree to which the proposed model 
under study (eg, the HADS) fits the empirical data (CFS/
ME and FM).35 37 Therefore, the GFI selected and used 
for analysis are: the χ2, which measures how well the 
hypothesised model fits this sample of CFS/ME and FM, 
or how much the data deviate from this model.35 Non- 
significant results (p>0.05) will confirm that the groups 
are responding to the questionnaires in the same way.35 
The χ2 divided by the df (CMIN/df) was used as it over-
comes any issues with sample size and will confirm if the 
current models from the questionnaire fit the current 
CFS/ME and FM data.37 38 The root mean square error 
of approximation39 is a discrepancy test that is sensitive 
to the complexity of the model specified, the number of 
parameters and quality of the model under study.37 The 
Comparative Fit Index assesses how superior the fit of the 
model proposed in the current study is compared with 
the null model, with the assumption that all latent vari-
ables are uncorrelated.40 The fit indices selected were 
based on their appropriateness of use for assessing the 
selected hypothesised models of the nine questionnaires 
in the CFS/ME and FM groups. Table 2 highlights the 
GFI and their measurement parameters.
The multigroup invariance test procedure
Following confirmation of good model fit for the nine 
individual questionnaires, multigroup invariance was used 
to test if the questionnaires held the same meaning for 
both groups, confirmed by the participants responding 







χ2 Low χ2 relative to df with an 
insignificant p level (p>0.05).
CMIN/df CMIN/df Ratio of χ2 to df ≤2 or 3, 




CFI Greater or equal to 0.95 for 
acceptance. Norm range of 
0–1.
Root mean 
square error of 
approximation
RMSEA <0.05–0.08 with CI of 90%.
Values <0.05 are better.
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to the questions in a similar manner. If the question-
naires are representative of the symptoms associated with 
CFS/ME and FM, and participant responses found to 
be invariant across the groups, it may be rational to say 
that CFS/ME and FM have the same underlying presen-
tation. If the model is found to be significant (p<0.05), 
it is said to be non- invariant across the groups and does 
not support the theory that participants with CFS/ME 
and FM are responding in a similar way to the ques-
tionnaire. Non- invariance would suggest that the nine 
questionnaires hold a different meaning for each group 
and that participants fitting the criteria for CFS/ME are 
reporting different symptom experiences to those fitting 
the criteria for FM.41 In this instance, the reason why the 
models are different needs to be investigated to identify 
which items are responsible for the differences between 
the two groups.42
Each item of the model was constrained individually to 
identify which factors/items are responsible for CFS/ME 
and FM groups approaching the questionnaires differ-
ently. A significant (p<0.05) result will identify the item/
items responsible for these differences.35
Patient and public involvement
Patients and the public were not involved in the design, 
conduct or reporting of this research.
RESULTS
Data were screened prior to analysis to confirm that all 
participants met the requirements of the inclusion and 
exclusion criteria. The age range of participants was 
between 17 and 75 years. The CFS/ME group (n=101) 
had a mean (M) age of 45.52 years and the SD was 
12.52 years, and for the FM group (n=107), M=47.20 
years, SD=10.77 years. The CFS/ME sample comprised 
85.2% (n=86) females and 14.8% (n=15) males. The 
FM group comprised 88.9% (n=95) females and 11.2% 
(n=12) males. Participants with CFS/ME 45.5% (n=46) 
were more readily diagnosed by a GP. In the case of FM, 
a greater portion were diagnosed by a rheumatologist 
(57.9% (n=62)).
All participants with CFS/ME confirmed that they 
had experienced their symptoms for the required ≥6 
months15 and ≥3 months for a FM diagnosis.4 The CFS/
ME group experienced their symptoms for a mean of 
10.69 years (SD=8.91 years), ranging from 1 year to 37 
years, exceeding the minimum requirements of 6 months. 
Participants with FM experienced symptoms for a mean 
of 12.62 years (SD=9.85 years), ranging from 1 year to 28 
years, exceeding the 3- month history required for a diag-
nosis of FM.
The American CDC Symptom Inventory was used to 
assess the additional symptoms associated for both CFS/
ME and FM. Both the CFS/ME 7.9% (n=8) and FM 1.8% 
(n=2) groups experienced a minimum of five additional 
symptoms listed by the American CDC criteria, confirming 
that both groups fulfilled the CFS/ME criteria, as they 
experienced ≥4 symptoms required.15 33 The maximum 
number of eight additional symptoms was experienced 
by the CFS/ME 49.0% (n=51) and FM 59.8% (n=61) 
groups (table 3). Table 3 highlights the number of partic-
ipants who confirmed they had experienced a particular 
symptom in the past 6 months.
The CFS/ME group (n=101) had a median score of 8 
and mode of 6 pain points selected, below the minimum 
requirement. The FM (n=107) group presented with a 
median of 14 and mode of 18 pain points, based on the 
ACR4 diagnostic criteria for FM, exceeding the minimum 
required number of 11 pain points. In the FM group, the 
most frequently reported number of pain points were 18 
(n=31). The total number of participants with ≥11 pain 
points were for CFS/ME: 29.7% (n=30) and FM: 76.6% 
Table 3 Mean scores for the diagnostic questionnaires for the CFS/ME and FM groups and the number of participants who 
confirmed that they experienced each symptom in the past 6 months on the American CDC Symptom Inventory
American CDC Symptom Inventory CFS/ME FM
Variable
Mean 
Score Yes n Yes % No n No %
Mean 
Score Yes n Yes % No n No %
Sore throat 3.79 77 76.2 24 23.8 3.59 82 76.6 25 23.4
Tender lymph nodes 4.60 81 80.2 20 19.8 4.25 83 77.6 24 22.4
Fatigue after exertion 12.43 101 100.0 0 0 12.99 106 99.1 1 0.9
Muscle aches and pains 9.51 95 94.1 6 5.9 13.79 107 100.0 0 0
Joint pain 7.78 85 84.2 16 15.8 11.48 105 98.1 2 1.9
Unrefreshing sleep 10.97 96 95.1 5 4.9 13.19 107 100.0 0 0
Headaches 6.27 93 92.1 8 7.9 9.96 95 88.8 12 11.2
Memory and concentration problems 9.37 96 95.1 5 4.9 9.62 104 97.2 3 2.8
Total degree of distress 64.72 – – – – 75.87 – – – –
Number of pain points 8.49 – – – – 13.59 – – – –
CDC, Centers for Disease Control and Prevention; CFS, chronic fatigue syndrome; FM, fibromyalgia; ME, myalgic encephalomyelitis.
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(n=82). Both groups of participants reported pain in 
differing areas of their body, which did not necessarily 
correspond with the number of pain points recorded.25
The Mann-Whitney U test results for the American CDC 
Symptom Inventory for CFS/ME and FM
The results from the Mann- Whitney U test for tender 
lymph nodes and/or swollen glands confirmed there were 
no significant differences between CFS/ME (median=2.5, 
n=101) and FM (median=5.0, n=107) groups (U=0.5, 
z=−0.004, p=0.9, r=0.003), where U=Mann- Whitney U, 
z=Kolmogorov- Smirnov test for evenly distributed groups, 
p=significance level and r=effect size. A significant differ-
ence between scores was identified for muscle aches and 
pains between the CFS/ME (median=10.0, n=101) and 
FM (median=16.0, n=107) (U=2611, z=−6.7, p=0.001, 
r=0.3), groups, with the FM confirming they experienced 
more muscle aches and pains than the CFS/ME group, 
and this difference was medium. These results confirmed 
that the FM group experienced more symptoms of unre-
freshing sleep than participants with CFS/ME. A signif-
icant difference was identified between the CFS/ME 
(median=12.0, n=101) and FM (median=16.0, n=107) 
groups; however, the magnitude of this difference was 
small (U=4023.5, z=−3.3, p=0.001, r=0.2).
The results identified that there were statistically no signif-
icant differences between the CFS/ME and FM groups on 
the CDC Symptom Inventory, with the exception of the total 
score, joint pain, muscle aches and pains and unrefreshing 
sleep. However, the magnitude of the difference measured by 
the effect size was small, with the exception of muscle aches 
and pains, where the difference was medium, suggesting this 
difference was not significant. The effect size explains the 
magnitude of any significant differences detected between 
variables, confirming how important differences are. Calcu-
lating the level of significance, the power and the effect 
size should increase the validity of the study. These results 
confirm that any differences between the CFS/ME and FM 
groups were not clinically significant, suggesting that both 
groups were similar at their baseline. These tests were carried 
out on all the questionnaires prior to SEM being performed.
Confirming a relationship between CFS/ME and FM
SEM results confirmed that both groups were invariant 
on all the questionnaires with the exception of the Amer-
ican CDC Symptom Inventory, the FIQ and the HADS 
(table 4). The results also confirmed that the criteria for 
metric invariance have not been fulfilled, suggesting that 
CFS/ME and FM groups were responding differently to 
items on these questionnaires (p<0.05) for each model. 
To identify which questions were responsible, each item 
was constrained individually. The results confirmed that, 
on the CDC Symptom Inventory, muscle aches and pains 
was the item of interest (χ2=55.44, df=25, ∆χ2=10.69, 
∆df=1, p=0.01 (p<0.05)). Two items on the FIQ were iden-
tified: the symptoms (χ2=104.16, df=63, ∆χ2=9.92, ∆df=1, 
p=0.02 (p<0.05)) and how tired have you been (χ2=104.16, 
df=63, ∆χ2=10.36, ∆df=1, p=0.01 (p<0.05)). On the HADS, 
the questions identified were: I can laugh and see the funny 
side of things (χ2=207.87, df=149, ∆χ2=5.45, ∆df=1, p=0.01 
(p<0.05)) and I can enjoy a good book or radio programme 
(χ2=208.05, df=149, ∆χ2=5.63, ∆df=1, p=0.01 (p<0.05)).
Due to the constraints of this research, it was not 
possible to perform a SEM on a model comprising all 
400 questions from the questionnaires used. Instead, 
the Syndrome Model was created comprising the three 
questionnaires responsible for non- invariance, which 
now incorporated the ACR Criteria for FM pain points 
(figure 1). The ACR criteria could not have been previ-
ously tested using SEM, because an independent model 
could not be created and tested as it only comprised 
one data point. Incorporating the ACR with these three 
Table 4 Summary of the results from the invariance testing of the questionnaires used to measure the symptoms of CFS/ME 
and the FM groups
Questionnaire χ2 df ∆χ2 ∆df P value CFI RMSEA
Invariance 
confirmed
American CDC Symptom Inventory 63.20 30 18.62 6 0.01 0.85 0.07 No
FIQ 1.74 71 29.49 9 0.01 0.92 0.06 No
MPQ 40.83 30 2.59 6 0.86 0.95 0.04 Yes
MFI 24.57 14 1.87 4 0.76 0.98 0.06 Yes
PSQI 40.83 30 2.59 6 0.86 0.95 0.04 Yes
SF-36 V2 116.26 43 13.14 9 0.09 0.89 0.09 Yes
HADS 223.81 160 21.39 12 0.04 0.94 0.04 No
MHLOC form C 420.89 366 14.01 14 0.45 0.84 0.05 Yes
RSES 122.12 79 4.88 9 0.85 0.95 0.05 Yes
Syndrome Model 27.69 12 10.49 4 0.07 0.91 0.08 Yes
CDC, Centers for Disease Control and Prevention; CFI, Comparative Fit Index; CFS, chronic fatigue syndrome; FIQ, Fibromyalgia Impact 
Questionnaire; FM, fibromyalgia; HADS, Hospital Anxiety and Depression Scale; ME, myalgic encephalomyelitis; MFI, Multidimensional 
Fatigue Inventory; MHLOC, Multidimensional Health Locus of Control Scale; MPQ, McGill Pain Questionnaire; PSQI, Pittsburgh Sleep Quality 
Index; RMSEA, root mean square error of approximation; RSES, Rosenberg Self- Esteem Scale.
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questionnaires increased the data points to create a test-
able model, where the sample size was appropriate to 
generate meaningful data. Invariance testing confirmed 
no differences between groups (p≤0.05) (table 4).
DISCUSSION
The need for contemporary research in this area 
was evident from the literature, which identified that 
although CFS/ME and FM may be discussed together, 
there are a limited number of studies which link CFS/
ME and FM.12 20–24 This study is unique as it measured 
the symptoms of CFS/ME and FM using self- assessment 
questionnaires to identify if the symptom experience was 
similar. The results confirmed that the characteristics of 
the participants, such as age and gender, concur with 
previously reported characteristics of patients with CFS/
ME and FM.11 25
Both groups satisfied the requirements of the CFS/
ME criteria15 33 and the FM criteria.4 The CFS/ME group 
recorded lower than the required number of pain points 
to meet the 1990 FM4 Criterion. However, with the publi-
cation of the reviewed criteria for FM,5 which removed 
the highly restrictive pain point assessment, and instead 
focuses on areas of pain, it may be fair to say in this 
instance that this strengthens the argument that the CFS/
ME group has satisfied the requirements of the revised 
2010 FM criteria. Historically, pain in FM and fatigue 
in CFS/ME have been the defining symptoms of the 
criteria to determine the possible management pathway. 
Although reported in each as an associated symptom, it 
is confirmed here that these are as problematic for both 
groups.6 9–11 25 This is supported as both groups reported 
that they had pain in differing areas of the body but not 
necessarily on a prescriptive pain point, which normally 
requires to be palpated with pressure to evoke an excruci-
ating pain response. By testing for any differences in the 
mean scores between groups, it was confirmed that any 
differences were not clinically significant. Although these 
results suggest that both groups have similar mean scores, 
it did not confirm that a relationship existed. This is why 
the SEM was performed to give meaning to these results.
SEM confirmed good model fit for the nine individual 
questionnaires to facilitate the invariance testing to confirm 
if the CFS/ME and FM participants were responding in a 
similar manner to the questionnaires. Overall, the results 
presented confirmed invariance between the latent vari-
ables on the models measured, suggesting that the CFS/
ME and FM groups were approaching the questionnaires 
in a similar manner as summarised in table 4. Invariance 
was confirmed for the symptoms measured by the MPQ, 
MFI and HRQoL measured by the SF-36 V2, MHLOC and 
the RSES. Following SEM, any differences in the mean 
scores identified and reported by McKay et al25 were 
further confirmed as being clinically insignificant and 
support the findings of the invariance testing.
In contrast, non- invariance was confirmed on the Amer-
ican CDC Symptom Inventory, the FIQ and the HADS. 
Two of these criteria were designed as syndrome specific 
and may account for this result. These differences may 
be due to the level of detail included for measuring that 
particular symptom and the criteria- based questionnaires 
not being sufficiently detailed to accurately measure the 
complexity of these symptoms. For example, consid-
eration should be given to these results in context with 
the findings from the symptom- specific questionnaires, 
such as the MPQ, which were confirmed as invariant, as 
this questionnaire provides a detailed account of pain 
and extensively measures the symptom experience.26 
However, considering our findings, it may have been erro-
neous to conclude that CFS/ME and FM were different 
based on the five questions (out of 400) identified as 
responsible for the non- invariance, taken from three 
of the questionnaires. Having considered all the results 
from the SEM’s performed, and the constraints imposed 
by the current study, it was proposed that the Syndrome 
Model be created (figure 1). The results from the SEM of 
the Syndrome Model subsequently confirmed invariance 
between groups (table 4). These results are encouraging 
in presenting the explanation that both groups have 
responded to the questions in a similar manner.
Taking these findings in context with the results 
from the individual SEM performed for the symptom 
Figure 1 The Syndrome Model and note changes made. C=CFS/ME, F=FM. CDC, Centers for Disease Control and 
Prevention; err, errors; FIQ, Fibromyalgia Impact Questionnaire; Anxiety and Depression = HADS, Hospital Anxiety and 
Depression Scale.
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questionnaires, it may be concluded that these partici-
pants with CFS/ME and FM are invariant across the symp-
toms and have the same overall syndrome experience 
impacting their quality of life.
However, our findings do not suggest that any single 
symptom, such as pain or fatigue, nor the magnitude 
of any similarities or differences between the individual 
symptoms are responsible for the cause, or any differ-
ences between CFS/ME and FM, but contribute to the 
whole symptom experience. This argument/conclusion is 
presented based on the evidence which highlights that to 
date, the aetiologies for both these groups have not been 
clearly identified, and therefore the symptoms of CFS/
ME and FM manifest as a single reality based on their 
responses to the questionnaires.4 5 15 25 Multiple possible 
contributing factors for CFS/ME have been discussed in 
the literature that include different viruses, infections and 
traumatic life events, with the WHO categorising CFS/
ME as a neurological condition of unknown origin G93.3 
(2013).23 44 45 In contrast, the exact aetiology of FM is pres-
ently unknown, but studies previously performed have 
suggested patients may have experienced trauma to an 
area of the body resulting in chronic pain associated with 
the central nervous system, infections, genetics (affecting 
the neurotransmitters) or hypersensitivity to pain.46–49 
However, despite vigorous searching, the cause of CFS/
ME and FM still remains to be identified.23 44 45 In this 
instance, it is the experience of the complex constellation 
of debilitating symptoms that is important and should be 
considered and managed appropriately to enhance the 
patients’ recovery and quality of life, despite the restric-
tions imposed by criteria or guidelines or lack thereof.
The findings presented complement research into the 
biomedical aspects of the syndromes and the manage-
ment options that may be available for CFS/ME and 
FM.1 24 Focus should be on enhancing quality of life 
by improving the symptom experience until definitive 
biomedical markers are identified for CFS/ME and FM. 
It is imperative that there is investment in biomedical 
research. In addition, with the CFS/ME NICE guidelines 
currently under review, and the proposal for a guide-
line for FM being rejected, these findings may be used 
to assist in any amendments and consideration for future 
guidelines.
Therefore, until the treatable cause is identified, both 
groups should be afforded whatever management options 
are available regardless of diagnostic criteria, classification 
of the syndrome, clinical experience, geographical loca-
tion or cost to improve quality of life. There is evidence 
to suggest that some of the current management options 
for CFS/ME and FM may be counterproductive. Treat-
ments such as cognitive–behavioural therapy, graded 
exercise therapy and pacing, yield mixed results in these 
patients, with some reporting that exercise may have a 
negative effect on their symptoms.24 50 51 Instead it may be 
beneficial to manage the patient’s symptoms individually 
to promote and support the patient’s quality of life. For 
example, consideration could be given to good medicine 
management of symptoms, involvement from specialist 
services such as nutritionists, chronic pain specialists, 
physiotherapists or occupational services and ensure the 
correct/appropriate delivery of care when required.
Strengths and limitations of this study
To our knowledge, this is the first study to assess the 
symptom experience of CFS/ME and FM using the 
methods described. This study brings attention to an area 
of CFS/ME and FM that has not been researched in a 
number of years and addresses the possible constraints 
imposed by pertinent guidelines or a lack thereof for 
CFS/ME and FM. Attention should focus on symptom 
management for improved quality of life, which is at the 
forefront in the lived experience of CFS/ME and FM.
The constraints of the sample size prevented the testing 
of a model incorporating all the questionnaires. In future, 
a substantially larger sample would be recommended to 
test the model.
The groups were found to be non- invariant on the 
American CDC Symptom Inventory and the FIQ. Both 
were designed to specifically assess CFS/ME and FM 
respectively, concluding that these criteria/question-
naires may each be biased towards the diagnosis they 
were designed for, as these findings suggest that CFS/ME 
and FM may manifest as a single reality for patients. In 
future, with the unclear origins of the aetiology, it may 
be recommended that these be reviewed or omitted and 
only generic questionnaires used, until a time when phys-
iological differences between CFS/ME and FM have been 
confirmed.
In future, it is recommended that the focus be on invest-
ment in education and training of clinicians responsible 
for diagnosing and managing patients with CFS/ME and 
FM. This is to enhance the management of the debili-
tating symptoms such as pain, fatigue, sleep disturbance 
and the additional debilitating symptoms of CFS/ME and 
FM. Optimal management may provide improvements in 
patients’ symptoms.
CONCLUSION
In conclusion from taking these results into context with 
the literature reviewed, this new approach confirms that 
both CFS/ME and FM symptom profiles and the daily 
challenges these patients are presented with are similar, 
making differentiation between the two symptom expe-
riences questionable. CFS/ME and FM may manifest as 
a single reality, with the evidence presented supporting 
the proposal to review the diagnostic criteria, guidelines 
and management and challenge the clinical opinion that 
divides CFS/ME and FM, or even rejects these syndromes 
as a reality. Therefore, consideration should be given to 
offering both groups the same management opportuni-
ties to address their symptoms and improve their health- 
related quality of life until research into the biomedical 
causes identifies and confirms the source of CFS/ME and 
FM.
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